Jump to content

Unity Biotechnology

From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Lady3mlnm (talk | contribs) at 14:34, 5 April 2021. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Unity Biotechnology
Company typePublic
Nasdaq: UBX
Russell 2000 Index component
IndustryBiotechnology, Pharmaceutical
PredecessorForge, Inc.
Founded2011; 14 years ago (2011) in California, United States of America
FoundersJudith Campisi, Jan van Deursen, Nathaniel “Ned” David, Daohong Zhou
Headquarters
South San Francisco, California
,
United States of America
Number of employees
70 (2018)
Websiteunitybiotechnology.com

Unity Biotechnology is a startup biotechnology company that develops drugs which target senescent cells.[1][2][3][4][5][6][7]

The company's products in development include UBX1325 that targets Bcl-xL, a mechanism to eliminate senescent cells in age-related eye diseases (in Phase 1 clinical trials for diabetic macular edema as of October 2020), UBX0101, targeting knee osteoarthritis (in Phase I clinical trials as of June 2018), and UBX1967, a preclinical product targeting ophthalmologic diseases.[8][9][10] All are senolytic medicines.

On May 3, 2018, the company went public on the Nasdaq exchange, raising $85 million at a market capitalization of $700 million.[11][9] Unity Biotechnology shares dropped 60% on August 17, 2020 after the company reported disappointing results from a clinical trial involving its lead drug candidate, UBX0101 in patients with moderate-to-severe painful osteoarthritis.[12]

See also

References

  1. ^ Brueck, Hilary (3 February 2016). "Mayo Clinic Taps Silicon Valley to Help People Age Gracefully". Fortune. Retrieved 19 February 2018.
  2. ^ Detrixhe, John (21 February 2018). "Crypto millionaires are funding research to reverse the aging process". Quartz (publication). Retrieved 19 February 2018.
  3. ^ Herkewitz, William (19 February 2018). "Scientists Can Now Radically Expand the Lifespan of Mice—and Humans May Be Next". Popular Mechanics. Retrieved 19 February 2018.
  4. ^ Ramsey, Lydia (10 November 2016). "A biotech startup that aims to rid our bodies of cells related to aging just got a big investment". Business Insider. Retrieved 19 February 2018.
  5. ^ Scudellari, Megan (25 February 2017). "To Stay Young, Kill Zombie Cells". Scientific American. Retrieved 19 February 2018.
  6. ^ Greenfieldboyce, Nell (3 February 2016). "Boosting Life Span By Clearing Out Cellular Clutter". Retrieved 19 February 2018.
  7. ^ Baker, Darren (11 February 2016). "Naturally occurring p16Ink4a-positive cells shorten healthy lifespan". Nature. 530 (7589): 184–189. doi:10.1038/nature16932. PMC 4845101. PMID 26840489.
  8. ^ "S-1". www.sec.gov. Retrieved 2018-10-12.
  9. ^ a b "Longevity Company Unity Biotechnology Stocks Soared After CEO Talks to CNBC | BioSpace". BioSpace. Retrieved 2018-10-12.
  10. ^ "Unity Biotechnology to focus on senolytic programs in ophthalmology, neurology". www.healio.com. Retrieved 2020-12-08.
  11. ^ CNBC (2018-05-02). "UNITY Biotechnology, Inc. Announces Pricing of Initial Public Offering of Common Stock". CNBC. Retrieved 2018-10-12.
  12. ^ "Buzzy anti-aging biotech Unity drops leading program after flop, shares in freefall". 2020-08-17.


Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Unity_Biotechnology&oldid=1016123649"